Nanovibronix (FEED) versus Its Peers Critical Review

Nanovibronix (NASDAQ:FEED) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its competitors? We will compare Nanovibronix to similar businesses based on the strength of its risk, valuation, dividends, profitability, analyst recommendations, institutional ownership and earnings.

Insider & Institutional Ownership

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 1.4% of Nanovibronix shares are held by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Nanovibronix and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	77	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 43.22%. Given Nanovibronix’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Nanovibronix and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.69 million	-$3.70 million	-0.07
Nanovibronix Competitors	$59.55 million	-$32.15 million	4.35

Nanovibronix’s competitors have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Nanovibronix has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s competitors have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Nanovibronix and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Summary

Nanovibronix competitors beat Nanovibronix on 8 of the 13 factors compared.

Nanovibronix Company Profile

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.